SYRE insider buying and SEC filings, explained
Spyre Therapeutics, Inc. · CIK 1636282
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Aeglea BioTherapeutics, Inc.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$42.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 1, 2026 | Planned (10b5-1) | Heidy King-Jones (Chief Legal Officer) sold 28,933 shares at about $91.03 ($2.6M), marked as a 10b5-1 plan trade. Holdings down 91% to 2,845 shares. | SEC filing Filed Oct 2, 2026, 9:30 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $92.01 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 3% to 537,540 shares. | SEC filing Filed Oct 2, 2026, 9:29 PM ET |
| Sep 30–Oct 1, 2026 | Planned (10b5-1) | Scott L Burrows (CFO) sold 25,000 shares between Sep 30 and Oct 1 at about $90.47 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 24% to 79,762 shares. | SEC filing Filed Oct 2, 2026, 9:29 PM ET |
| Sep 1–2, 2026 | Planned (10b5-1) | Heidy King-Jones (Officer) sold 28,399 shares between Sep 1 and Sep 2 at about $87.35 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 91% to 2,845 shares. | SEC filing Filed Sep 3, 2026 |
| Sep 1–2, 2026 | Planned (10b5-1) | Scott L Burrows (CFO) sold 25,732 shares between Sep 1 and Sep 2 at about $88.75 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 24% to 79,762 shares. | SEC filing Filed Sep 3, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $87.29 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 3% to 552,540 shares. | SEC filing Filed Sep 3, 2026 |
| Aug 7, 2026 | Planned (10b5-1) | Jeffrey W. Albers (Director) sold 23,000 shares directly and indirectly (by entity) at about $104.53 ($2.4M), marked as a 10b5-1 plan trade. Direct holdings down 100% to 0 shares. | SEC filing Filed Aug 10, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Scott L Burrows (CFO) sold 7,500 shares at about $95.57 ($717K), marked as a 10b5-1 plan trade. Holdings down 7% to 97,994 shares. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $95.51 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 3% to 567,540 shares. | SEC filing Filed Aug 5, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Scott L Burrows (CFO) sold 7,500 shares at about $87.74 ($658K), marked as a 10b5-1 plan trade. Holdings down 7% to 97,994 shares. | SEC filing Filed Jul 2, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Sheldon Sloan (Chief Medical Officer) sold 8,334 shares at about $87.70 ($731K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jul 2, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $87.69 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 3% to 582,540 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Michael Thomas Henderson (Director) sold 20,000 shares at $100.00 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 23% to 68,606 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Sheldon Sloan (Chief Medical Officer) sold 8,333 shares at $75.00 ($625K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jun 3, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $70.43 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 2% to 597,540 shares. | SEC filing Filed Jun 3, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Scott L Burrows (CFO) sold 7,500 shares at about $71.06 ($533K), marked as a 10b5-1 plan trade. Holdings down 7% to 97,994 shares. | SEC filing Filed Jun 3, 2026 |
| May 8, 2026 | Planned (10b5-1) | Michael Thomas Henderson (Director) sold 80,000 shares at about $74.40 ($6.0M), marked as a 10b5-1 plan trade. Holdings down 47% to 88,606 shares. | SEC filing Filed May 8, 2026 |
| May 1, 2026 | Planned (10b5-1) | Sheldon Sloan (Chief Medical Officer) sold 78,333 shares at about $71.50 ($5.6M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed May 1, 2026 |
| May 1, 2026 | Planned (10b5-1) | Scott L Burrows (CFO) sold 12,500 shares at $71.37 ($892K), marked as a 10b5-1 plan trade. Holdings down 11% to 97,994 shares. | SEC filing Filed May 1, 2026 |
| May 1, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $71.37 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 2% to 612,540 shares. | SEC filing Filed May 1, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Scott L Burrows (CFO) sold 7,500 shares at about $49.34 ($370K), marked as a 10b5-1 plan trade. Holdings down 7% to 97,994 shares. | SEC filing Filed Apr 3, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $49.33 ($740K), marked as a 10b5-1 plan trade. Holdings down 2% to 627,540 shares. | SEC filing Filed Apr 3, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Sheldon Sloan (Chief Medical Officer) sold 7,958 shares at $50.00 ($398K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Scott L Burrows (CFO) sold 2,500 shares at about $40.65 ($102K), marked as a 10b5-1 plan trade. Holdings down 2% to 97,994 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $42.19 ($633K), marked as a 10b5-1 plan trade. Holdings down 2% to 642,540 shares. | SEC filing Filed Mar 3, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $32.80 ($492K), marked as a 10b5-1 plan trade. Holdings down 2% to 657,540 shares. | SEC filing Filed Feb 4, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $30.68 ($460K), marked as a 10b5-1 plan trade. Holdings down 2% to 671,907 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 1, 2025 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 15,000 shares at about $29.02 ($435K), marked as a 10b5-1 plan trade. Holdings down 2% to 686,907 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Cameron Turtle (CEO and Director) sold 45,000 shares at about $23.33 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 6% to 701,907 shares. | SEC filing Filed Nov 5, 2025 |
29 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 4:02 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SYRE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.